|Bid||1,380.00 x 200|
|Ask||1,626.00 x 5000|
|Day's Range||1,407.00 - 1,416.00|
|52 Week Range||1,290.00 - 1,850.00|
|PE Ratio (TTM)||295.31|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
More competition could help overcome the suspicion over drug prices that plagues the would-be business partners' dealings.
CVS Health Corp's Omnicare unit has agreed to pay $23 million to resolve a whistleblower lawsuit alleging that it took kickbacks from a drugmaker to promote two antidepressants, according to settlement papers released on Friday. The accord, confirmed by the U.S. Attorney's Office in Boston, will resolve a lawsuit against the pharmacy operator filed in 2007 by two former employees of drugmaker Organon USA Inc on behalf of the federal government and various states. CVS in a statement said the alleged conduct at issue took place before it acquired Omnicare in 2015.
CVS Health's business has suffered a series of setbacks this past year. Is its dividend at risk?